Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00406536 · ClinicalTrials.gov registry record · Phase 2

Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

A Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by Avanti Polar Lipids.

Completed
Registry status
Phase 2
Development phase
110
Enrollment target
1
Study location

NCT00406536: Completed Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency, sponsored by Avanti Polar Lipids.

NCT00406536 is a Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency that has completed, run by Avanti Polar Lipids. The registered enrollment target is 110 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00406536, a Phase 2 study of Cystic Fibrosis and Pancreatic Insufficiency, has completed, sponsored by Avanti Polar Lipids.

COMPLETED
Registry status
Phase 2
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The purpose of this phase II research study is to evaluate the effectiveness of the next generation LYM-X-SORB™ in improving the essential fatty acid (EFA) and choline status for children and adolescents with Cystic Fibrosis (CF) and pancreatic insufficiency (PI).

Conditions Studied

Cystic Fibrosis Pancreatic Insufficiency

Interventions

  • DIETARY_SUPPLEMENT Lym-X-Sorb powder
  • DIETARY_SUPPLEMENT Placebo powder

Study Locations (1)

Pennsylvania

  • Children's Hospital of Philadelphia (CHOP) - Philadelphia

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2007-01
Est. Completion 2012-06
Phase Phase 2
Avanti Polar Lipids

1 total trials

What the finished NCT00406536 record still lists

NCT00406536 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (39% lower).

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Lym-X-Sorb powder is the first listed.

NCT00406536 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00406536 about?

NCT00406536 is a clinical study titled "Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI". The purpose of this phase II research study is to evaluate the effectiveness of the next generation LYM-X-SORB™ in improving the essential fatty acid (EFA) and choline status for children and adolescents with Cystic Fibrosis (CF) and pancreatic insufficiency (PI).

What is the current status of trial NCT00406536?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2007-01. Estimated completion is 2012-06.

What conditions does trial NCT00406536 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Pancreatic Insufficiency.

What interventions are being tested in trial NCT00406536?

The interventions under investigation include: Lym-X-Sorb powder (DIETARY_SUPPLEMENT), Placebo powder (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00406536?

This trial is sponsored by Avanti Polar Lipids, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00406536 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00406536's enrollment target sits among peer trials

110 56th of 169 higher than 114 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00406536, the US trial registry maintained by the National Library of Medicine. NCT00406536 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.